跳至主要内容
临床试验/NCT05924412
NCT05924412已完成4 期

A Randomized Comparison Between Parecoxib and Placebo Added to a Standard Perioperative Analgesic Protocol for Total Knee Arthroplasty

University of Chile1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年7月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Morphine consumption

研究概览

简要总结

Early mobilization and rehabilitation can be difficult after total knee arthroplasty (TKA) due to a high incidence of moderate to severe postoperative pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are important to multimodal analgesic protocols. Parecoxib is an NSAID that selectively inhibits the enzyme cyclooxygenase-2 (COX-2). Clinical trials have shown that it does not alter platelet function or gastric mucosa. A recent study, after comparing ketorolac and parecoxib used at the same time in infiltration and systemically, found no differences in perioperative analgesia with a tendency to less bleeding in the parecoxib group. This randomized study will compare the effectiveness of adding a COX-2 inhibitor in the pain management of patients undergoing TKA as part of a multimodal analgesia regimen. The morphine consumption was selected as the primary outcome. The study hypothesis is that patients receiving parecoxib would have a lower opioid consumption.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ASA I - III BMI 20 - 35 (kg/m2)

排除标准

  • Adults who are not capable of giving their own consent
  • Pre-existing neuropathy (assessed in the history and physical examination)
  • Coagulation disturbance (assessed on history and physical examination, if clinically necessary, by blood test, i.e. platelets ≤ 100,000, international normalized ratio ≥ 1.4 or prothrombin time ≥ 50)
  • Renal failure (assessed by history and physical examination, if considered clinically necessary, by blood test, i.e. creatinine ≥ 1.04 mg/dl)
  • Hepatic impairment (assessed by history and physical examination, if considered clinically necessary, by blood tests, i.e. transaminases (GGT ≥ 50 u/lt)
  • Allergy to local anesthetics, morphine, paracetamol, ketorolac or parecoxib
  • Pregnancy
  • Chronic pain syndromes that require the use of opioids at home
  • Known history of sulfa allergy
  • History of ischemic heart disease
  • History of chronic gastritis or peptic ulcer

研究组 & 干预措施

Parecoxib

Experimental

This arm will receive intravenous parecoxib in the intraoperative period.

干预措施: Intravenous study drug (Drug)

Placebo

Placebo Comparator

This arm will receive a placebo intravenous injection containing saline solution in the same volume as the intervention group

干预措施: Intravenous saline solution (Other)

结局指标

主要结局

Morphine consumption

时间窗: 24 hours

Morphine consumed postoperatively during the first 24 hrs utilizing a patient-controlled analgesia device programmed 1mg/ml morphine solution, no infusion, 1ml dose, 8 minutes lockout.

次要结局

  • Basal quadriceps strength in the operative side(1 hour before surgery)
  • Nerve block performance time(5 minutes after anesthesia induction (before surgical incision))
  • Incidence of Block complications(5 minutes after anesthesia induction and before surgical incision)
  • Basal level of pain during leg extension in the operative side(1 hour before surgery)
  • Basal plasmatic creatinine(1 hour before surgery)
  • Time to first morphine dose request(24 hours)
  • Postoperative dynamic pain level at 12 hours(12 hours)
  • Postoperative dynamic pain level at 48 hours(48 hours)
  • Morphine consumption during first 48 hours(48 hours)
  • Incidence of opioid related side effects(48 hours)
  • Incidence of NSAIDs related clinical side effects(48 hours)
  • Postoperative static pain level at 3 hours(3 hours)
  • Postoperative dynamic pain level at 3 hours(3 hours)
  • Postoperative static pain level at 6 hours(6 hours)
  • Postoperative dynamic pain level at 6 hours(6 hours)
  • Postoperative dynamic pain level at 24 hours(24 hours)
  • Postoperative static pain level at 48 hours(48 hours)
  • Medial malleolus sensory block level(24 hours)
  • Postoperative quadriceps strength(24 hours)
  • Postoperative static pain level at 12 hours(12 hours)
  • Postoperative static pain level at 24 hours(24 hours)
  • Incidence of restriction to perform physiotherapy(48 hours)
  • Postoperative plasmatic creatinine level(48 hours)
  • Lateral malleolus sensory block level(24 hours)

研究者

发起方
University of Chile
申办方类型
Other
责任方
Principal Investigator
主要研究者

Julian Aliste

Associate Professor

University of Chile

研究点 (1)

Loading locations...

相似试验

Parecoxib in Total Knee Arthroplasty | 临床试验